Literature DB >> 9126855

Computerized neuropsychological tests in the early detection of dementia: prospective findings.

K S Fowler1, M M Saling, E L Conway, J M Semple, W J Louis.   

Abstract

This longitudinal study examines the sensitivity of 2 computerized neuropsychological tests, delayed matching to sample and paired associate learning, to early dementia of the Alzheimer type (DAT). Normal controls, patients in the early stages of DAT, and individuals with questionable dementia (QD) were studied. At 6 and 12 months after initial presentation, almost half of the QD group exhibited lower scores on the computerized subtests, maintaining their scores on standard testing. Over the same period NC subjects maintained their performance levels, while DAT patients continued to deteriorate. Linear discriminant function analyses of the computerized subtests at 6 and 12 months correctly classified 100% of the early DAT patients. Eighty-four and 79 percent of normal controls were correctly classified at 6 and 12 months respectively. Further development of these subtests for the detection of early dementia and the documentation of ongoing change in DAT is warranted. The findings are discussed in terms of the special sensitivity of these tests to the neuropathology of Alzheimer's Disease.

Entities:  

Mesh:

Year:  1997        PMID: 9126855

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  26 in total

1.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials.

Authors:  Jonathan M Payne; Belinda Barton; E Arthur Shores; Kathryn N North
Journal:  J Neurol       Date:  2012-08-09       Impact factor: 4.849

3.  Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys.

Authors:  Michael A Taffe; Michael R Weed; Tannia Gutierrez; Sophia A Davis; Lisa H Gold
Journal:  Psychopharmacology (Berl)       Date:  2002-01-22       Impact factor: 4.530

4.  Advances in designs for Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Heath Gould; Kate Zhong
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

5.  Neuropsychological prediction of conversion to dementia from questionable dementia: statistically significant but not yet clinically useful.

Authors:  J Tian; R S Bucks; J Haworth; G Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

Review 6.  Consideration of species differences in developing novel molecules as cognition enhancers.

Authors:  Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson
Journal:  Neurosci Biobehav Rev       Date:  2012-10-12       Impact factor: 8.989

7.  Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys.

Authors:  Stefani N Von Huben; Sophia A Davis; Christopher C Lay; Simon N Katner; Rebecca D Crean; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2006-03-15       Impact factor: 4.530

Review 8.  Early detection of memory impairment in Alzheimer's disease: a neurocognitive perspective on assessment.

Authors:  Georgia Lowndes; Greg Savage
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

9.  Chronic manganese exposure impairs visuospatial associative learning in non-human primates.

Authors:  J S Schneider; C Williams; M Ault; T R Guilarte
Journal:  Toxicol Lett       Date:  2013-06-15       Impact factor: 4.372

10.  The Indiana faces in places test: preliminary findings on a new visuospatial memory test in patients with mild cognitive impairment.

Authors:  Leigh J Beglinger; Kevin Duff; David J Moser; Stephen A Cross; David A Kareken
Journal:  Arch Clin Neuropsychol       Date:  2009-08-13       Impact factor: 2.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.